Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company that focuses on pioneering novel cancer therapies. The company is engaged in the discovery, development, and investigation of cancer treatments, particularly those addressing high unmet medical needs.

Karyopharm Therapeutics Inc.

Karyopharm eLibrary

Domain Not Resolving

HSTS

Amazon

Mobile Non Scaleable Content

DNSSEC

reCAPTCHA

Cloudflare CDN

Facebook Sharer

Amazon Virginia Region

ASP.NET

Chief Compliance Officer & VP, Legal

James Accumanno

Chief Commercial Officer

John Demaree

Owner

Mark Jensen

Cofounder

Michael Kauffman

Engineering

Michael Mano

Chief Financial Officer

Michael Mason

Legal

Nancy Smith

Co-Founder

Nathaly Jaquez

Executive VP & Chief Development Officer

Ran Frenkel

Chief Medical Officer

Reshma Rangwala

Deepika R Pakianathan

Mansoor Raza Mirza

Ed Roberts

Lynda Chin

Giulio Draetta

Christopher Kirk

Pamela Silver

Garen Bohlin

Sharon Shacham

Founder

Brian Austad

SVP, Pharmaceutical Sciences

Ronald A. DePinho

Sohanya Cheng

SVP Sales & Chief Commercial Officer

John McCartney

Senior Director, Product Leadership

Wen Chen

Senior Director of Pharmaceutical Sciences, Formulation Development

New England Health Care Companies (Top 10K)

Pharmaceutical Companies With More Than 50 Employees (Top 10K)

Pharmaceutical Companies With More Than $10M in Revenue

East Coast Companies With More Than $10M in Revenue (Top 10K)

Karyopharm Therapeutics is a biopharmaceutical company with a focus on the development of novel drugs for the treatment of cancer, inflammation, and diseases related to cell proliferation. Karyopharm Therapeutics is developing small molecule drugs that will modulate the activity of critical pathways in cancer, inflammation, and cell proliferation (e.g. FOXO, NFÐºB, P53, pRB) by targeting the nuclear pore complex machinery, which controls the import and export of proteins between the nucleus and cytoplasm. To successfully control transport through the nuclear pore complex, the company will use its unique technology platform, developed by Sharon Shacham, to identify novel small molecules, optimize them into clinical candidates, and evaluate them in subsequent human clinical studies.

Avidity Partners

Post-IPO Equity - Karyopharm Therapeutics

Foresite Capital

Series B - Karyopharm Therapeutics

Delphi Ventures

Chione

Series A - Karyopharm Therapeutics

Multiple Myeloma Research Foundation

Grant - Karyopharm Therapeutics

Newton

Massachusetts

United States

North America

Karyopharm Therapeutics

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or ...

Karyopharm to Participate at the Jefferies Global Healthcare Conference

Karyopharm Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast ...

Philippines

Asia

El Salvador

Portugal

Europe

Estonia

HTML5

Google Compute Engine

Vimeo

Wordpress

Google Analytics

F5 NGINX

Office 365

DigiCert

jQuery

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 20, 2024 9:11 AM	310a5ba6
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 20, 2024 9:11 AM	263f735d
crunchbase trigger	general	Oct 30, 2024 1:02 PM	dd7b2698
crunchbase profile	general	Oct 30, 2024 3:05 PM	312a7586
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	13f87dbe
peers	general	Sep 20, 2024 9:11 AM	f623d8aa
news basic	general	Sep 20, 2024 9:11 AM	b48a18a5
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:KARYOPHARM

Karyopharm Therapeutics Inc.

Last Close

0.78

22/11 21:00

Market Cap

107.99M

Beta: -

Volume Today

500.06K

Avg: -